New CAR t cell therapy takes on Hard-to-Treat ovarian cancer

NCT ID NCT06305299

Recruiting now Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new treatment for ovarian cancer that has returned after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is to find a safe dose and see what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iC9-CAR.B7-H3 T cells (a type of immune cell therapy)
What this could lead to: If this works, it could point toward a new treatment option for ovarian cancer that has stopped responding to standard chemotherapy.
What could go wrong: This is a very early phase 1 trial with only 27 participants, so it is primarily testing safety, not effectiveness. There are risks of serious side effects like cytokine release syndrome and nerve toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial ovarian cancer ovarian carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER OVARIAN CANCER OVARY NEOPLASM RECURRENT

Contacts and locations

Locations

Lineberger Comprehensive Cancer Center
RECRUITING

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.